Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| WI231434 IIR | Other Grant/Funding Number | Pfizer Inc., a Delaware corporation with an office of business at 235 East 42nd Street, New York, NY 10017 ("Pfizer" |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Ljubljana School of Medicine, Slovenia | OTHER |
| Harvard Medical School (HMS and HSDM) | OTHER |
Not provided
Not provided
Not provided
The overall goals of this study are to 1) assess awareness of interest in the use of pharmacotherapy for smoking cessation in Croatia and Slovenia, countries in Central Europe with very high smoking prevalence, and 2) investigate whether cytisine is at least as feasible and effective as varenicline in helping smokers to quit in a real-life setting: family medicine practices in Croatia and Slovenia. The investigators propose to survey patients from 40 primary care practices (20 in Croatia and 20 in Slovenia) to assess desire to quit smoking and awareness and interest in pharmacotherapy. Additionally, 380 patients with interest in quitting smoking will be randomly assigned to use varenicline or cytisine to help quit smoking.
The investigators hypothesize that cytisine is at least as feasible and effective as varenicline in helping smokers from primary care practices in Croatia and Slovenia to quit smoking.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Varenicline (Champix) | Active Comparator | Varenicline treatment will start one week prior to the patient's target quit date at 0.5 mg/day for days 1-3, 0.5 mg twice daily for days 4-7. On the target quit date (day 8), the dose will be increased to 1 mg twice daily and maintained for day 8-week 12. Patients will receive weekly calls during the first 4 weeks and at weeks 8, 12, and 24 to inquire about medication adherence and smoking status, motivate the patient to take the medication, encourage them not to smoke, and ask about possible side effects or other issues. |
|
| Cytisine (Tabex) | Active Comparator | Patients will be asked to reduce their smoking during the first 4 days of treatment with aim to quit on the 5th day (target quit date). Cytisine treatment will follow standard manufacturer's dosing protocol of one tablet every 2 hours through the waking day (up to 6 tablets per day) for days 1-3, one tablet every 2.5 hours (up to 5 tablets per day) for days 4-12, one tablet every 3 hours (up to 4 tablets per day) for days 13-16, one tablet every 4-5 hours (3 tablets per day) for days 17-20, and one tablet every 6 hours (2 tablets per day) for days 21-25. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Varenicline | Drug | 191 patients will receive varenicline for 12 weeks and regular phone calls with brief counseling Tabex: 188 patients will receive cytisine for 25 days and regular phone calls with brief counseling |
| Measure | Description | Time Frame |
|---|---|---|
| Seven day abstinence from tobacco | Proportion of patients in the varenicline and cytisine groups who self-report seven-day abstinence from tobacco. | 12-weeks following target quit date |
| Measure | Description | Time Frame |
|---|---|---|
| Seven day abstinence from tobacco country and practice | Proportion of patients in the varenicline and cytisine groups who self-report seven-day abstinence from tobacco. | 4-weeks following target quit date |
| Seven day abstinence from tobacco |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Stjepan Oreskovic, PhD | University of Zagreb | Principal Investigator |
| Sanja Percac Lima, PhD, MD | Massachusetts General Hospital | Principal Investigator |
| Hrvoje Tiljak, PhD | University of Zagreb | Study Chair |
| Janez Rifel, PhD | University of Ljubljana School of Medicine | Study Chair |
| Jeffrey M Ashbruner, PhD, MPH | Massachusetts General Hospital | Study Chair |
| Zalika Klemenc Ketis, MD, PhD | University of Ljubljana School of Medicine | Study Chair |
| Tin Oreskovic | IBM Chief Analytics Office, MIT-IBM AI Lab | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Zagreb School of Medicine | Zagreb | 10000 | Croatia | |||
| University of Ljubljana School of Medicine |
Not provided
After completion of the data collection and analysis
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D016540 | Smoking Cessation |
| ID | Term |
|---|---|
| D015438 | Health Behavior |
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068580 | Varenicline |
| C004712 | cytisine |
| ID | Term |
|---|---|
| D001552 | Benzazepines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Cytisine | Drug | 185 patients will receive cytisine for 25 days and regular phone calls with brief counseling |
|
|
Proportion of patients in the varenicline and cytisine groups who self-report seven-day abstinence from tobacco.
| 8-weeks following target quit date |
| Seven day abstinence from tobacco | Proportion of patients in the varenicline and cytisine groups who self-report seven-day abstinence from tobacco. | 24-weeks following target quit date |
| Seven day abstinence from tobacco | Repeated measures of proportion of patients in the varenicline and cytisine groups who self-report seven-day abstinence from tobacco | 4, 8, 12, and 24 weeks following target quit date |
| Continuous smoking cessation | Proportion of patients who self-report continuous smoking cessation in the varenicline and cytisine groups (5 cigarettes allowed) | 4, 8, 12, and 24 weeks following target quit date |
| Medication adherence | Self report of adherence to assigned treatment protocol, including count of pills and stopping treatment (including reasons) | 1, 2, 3, 4, 8, 12 weeks following target quit date |
| Side effects | Self-report of any unintended sign, symptom, or other health-related issue that occurs during treatment with varenicline or cytisine | 4, 8, 12, and 24 weeks following target quit date |
| Ljubljana |
| 1000 |
| Slovenia |
| D011810 | Quinoxalines |